SHOULDER INNOVATIONS, INC. (SI): Results of Operations and Financial Condition
SHOULDER INNOVATIONS, INC. (SI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Shoulder Innovations Reports Second Quarter 2026 Financial Results and Raises Full Year Outlook Generates First Half 2026 Revenue Growth of 60% Grand Rapids, MI – August 6, 2026 – Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE: SI), a commerc
How this was made
The 30-second read
Why it matters
The primary tradable items are the raised full-year revenue range, Q2 revenue and gross margin improvements, and the company’s stated commercial launch progress plus debt refinancing that increases working-capital flexibility.
Market read
Traders can reassess near-term expectations based on the raised FY2026 revenue outlook and the disclosed Q2 growth in implant systems sold and gross margin.
What to watch
SG&A and R&D both increased sharply year over year, and the filing highlights public-company transition costs and robotic platform development, which may pressure future profitability despite revenue growth.
Shoulder Innovations Reports Second Quarter 2026 Financial Results and Raises Full Year Outlook
Net revenue grew 56%, gross margin expanded to 78.3%, implant-system volume increased approximately 50%, and the company raised full-year 2026 net revenue guidance. Operating loss widened as the company increased commercial and research and development investment.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Net revenueGAAP | $17.2 million | – | 56% |
| First half 2026 revenue growthother | 60% | – | – |
| Gross marginGAAP | 78.3% | – | – |
| Average selling price of implant systemsother | $7,674 | – | 5% |
| Total implant systems soldother | 2,238 | – | approximately 50% |
| Selling, general and administrative expensesGAAP | $20.1 million | – | 56% |
| Research and development expensesGAAP | $3.4 million | – | 141% |
| Operating lossGAAP | $10.0 million | – | – |
| Net lossGAAP | $10.2 million | – | – |
| Adjusted EBITDAnon-GAAP | loss of $8.0 million | – | – |
full year 2026 outlook
- Revenue$67 million to $69 million
- Notegrowth of approximately 42% to 46% over full year 2025 net revenue
What drove it
- Net revenue growth was due to an increase in the number of implant systems sold and an increase in the number of customers.
- Gross-margin expansion was due to increases in the average selling price of implant systems and benefits from negotiated cost reduction programs.
- The company initiated full commercial launch of the N-22 glenosphere for patients with metal hypersensitivity.
- The company initiated full commercial launch of a new titanium plasma spray (TPS) baseplate line extension for reverse procedures.
- The company expanded its commercial organization in the second quarter to support increased business scale.
Concerns
- Selling, general and administrative expenses increased 56% to $20.1 million, primarily reflecting commercial-organization investments, higher variable selling expenses, and increased public-company costs.
- Research and development expenses increased 141% to $3.4 million due to new product development efforts, including development related to the robotic platform strategic partnership.
- Operating loss was $10.0 million, compared to a loss of $5.9 million in the second quarter of 2025.
What to watch
- Execution against full-year 2026 net revenue guidance of $67 million to $69 million.
- Commercial adoption following the launches of the N-22 glenosphere and TPS baseplate line extension.
- Implant-system volume, average selling price, and customer growth.
- The pace of commercial and research and development spending relative to revenue growth and gross-margin performance.
- Use of the credit facilities and working capital capacity.
Balance sheet and cash flow
- As of June 30, 2026, cash and cash equivalents, and marketable securities totaled $99.0 million.
- Closed two new credit facilities for an aggregate amount of up to $50 million with Stifel Venture Banking, refinancing existing debt and adding undrawn working capital capacity.
Analysis
Shoulder Innovations reported a strong top-line quarter, with net revenue increasing 56% to $17.2 million. Management attributed the increase to more implant systems sold and more customers. The company sold 2,238 total implant systems, an approximate 50% increase over the second quarter of 2025, while average selling price increased 5% to $7,674. The release also highlighted first-half 2026 revenue growth of 60%.
Mix and execution supported profitability at the gross-profit level. Gross margin increased to 78.3% from 76.2%, driven by higher average selling prices and negotiated cost reduction programs. The margin improvement occurred alongside commercial expansion and product activity, including full commercial launches of the N-22 glenosphere for patients with metal hypersensitivity and a TPS baseplate line extension for reverse procedures.
Operating spending rose materially as the company invested for scale. Selling, general and administrative expenses increased 56% to $20.1 million, reflecting commercial investments, higher variable selling costs, and public-company costs. Research and development expense increased 141% to $3.4 million, including work related to the robotic platform strategic partnership. These investments contributed to operating loss widening to $10.0 million from a loss of $5.9 million, despite the gross-margin expansion.
Net loss improved to $10.2 million from a net loss of $19.2 million, and adjusted EBITDA loss improved to $8.0 million from a loss of $18.1 million. The company said the prior-year period included a significant charge from changes in the fair value of its preferred stock warrant liability and Series E purchase option. As of June 30, 2026, cash and cash equivalents and marketable securities totaled $99.0 million, and the company closed credit facilities of up to $50 million that refinanced existing debt and added undrawn working capital capacity.
Management raised full-year 2026 net revenue guidance to $67 million to $69 million, representing growth of approximately 42% to 46% over full-year 2025 net revenue. The guide was raised from the $65 million to $68 million range cited in the release, although no prior outlook document was supplied for formal guidance-performance comparison. The central execution items are whether implant volume, customer additions, pricing, and gross margin remain durable while commercial and product-development investment continues.
Management, verbatim
Our second quarter results build on a strong start to the year and reflect remarkable momentum across every dimension of our business. We continued to rapidly onboard new surgeons against a large, underpenetrated market opportunity, deepened utilization within our existing surgeon base, and advanced a broad and increasingly differentiated product pipeline. This performance resulted in net revenue growth of 56% and implant volume growth of approximately 50%, enabling us to increase our outlook for the full year.
Rob Ball, CEO of Shoulder Innovations
Our confidence in what lies ahead has never been stronger. The commercial organization we’ve built continues to perform, our innovation pipeline is growing, and our conviction in the team’s ability to execute is high. With a strengthened financial foundation following our recent debt refinancing, we believe Shoulder Innovations remains in the early stages of what we can accomplish in transforming shoulder surgical care, and we look forward to demonstrating that in the back half of 2026 and beyond.
Rob Ball, CEO of Shoulder Innovations
Not in the filing
stated, not guessed- GAAP earnings per share
- Non-GAAP earnings per share
- Prior-quarter comparisons for reported metrics
- Segment revenue disclosure
- Operating cash flow
- Free cash flow
- Capital expenditures
- Debt outstanding balance
- Share repurchases
- Dividends
- Guidance for gross margin, operating expenses, tax rate, earnings per share, operating cash flow, or free cash flow
- Previous-release outlook required for vs_prior_guidance comparison
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is an SEC 8-K (Item 2.02) with an attached earnings release covering Q2 2026 results and updated FY2026 net revenue guidance.
Ticker impact
Shoulder Innovations reported Q2 2026 net revenue of $17.2M (+56% YoY) and raised FY2026 guidance to $67M-$69M.
Bias toward upside on the guidance raise, with follow-through dependent on whether investors focus more on revenue growth or on widening operating loss and R&D spend.
The filing discloses a concrete FY outlook increase, Q2 revenue and gross margin improvements, and specific commercial launches, but also shows operating loss and R&D expense growth that can temper the reaction.
Market effects
Could modestly improve sentiment toward commercial-stage medical device companies showing scale-up traction and margin expansion.
Limited, as the disclosure is company-specific with no broader regional macro/regulatory signal.
Low, as the news is not tied to global supply chains or international regulatory actions.
Counterpoint
Investors may discount the guidance raise if operating loss and R&D intensity continue to rise faster than revenue, implying margin durability risk.
Key entities
- companyShoulder Innovations, Inc.
Commercial-stage shoulder surgical technology company reporting Q2 2026 results and raising FY2026 net revenue guidance.
- credit_facility_counterpartyStifel Venture Banking
Provided credit facilities totaling up to $50 million, refinancing existing debt and adding undrawn working capital capacity.
- product_launchN-22 glenosphere
Company initiated full commercial launch for patients with metal hypersensitivity.
- product_launchTitanium plasma spray (TPS) baseplate line extension
Company initiated full commercial launch for reverse procedures.
